Alnylam Pharma (ALNY) Tops Q3 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
JPMorgan Upgrades Alnylam Pharmaceuticals (ALNY) to Overweight
November 9, 2017 4:37 AM ESTJPMorgan upgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Neutral to Overweight with a price target of $162.00 (from $86.00).
Analyst Anupam Rama believes givosiran remains underappreciated on the Street and as a driver of upside for the company. The analyst also is expecting a smooth... More
Alnylam Pharmaceuticals (ALNY) PT Raised to $158 at Barclays on 3Q Report; 'Multiple Programs Progressing to Approval/Late-Stage Development'
November 8, 2017 11:54 AM ESTBarclays raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $158.00 (from $127.00) while maintaining a Overweight rating, following the company's third quarter earnings report.
Analyst Gena Wang notes a positive outlook on the shares, as the company reported third quarter earnings per share results above... More
Alnylam Pharmaceuticals (ALNY) PT Raised to $107 at Stifel
November 8, 2017 10:07 AM ESTStifel raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $107.00 (from $83.00) while maintaining a Hold rating following non-eventful earnings.
Analyst Stephen Willey views the initiation of the P3 ENVISION trial as an incremental positive.
... More